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Risk Factors for Bloodstream Infections due to Extended-spectrum 
b-lactamase-producing Escherichia coli
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BACKGROUND/PURPOSE: The risk factors for production of extended-spectrum β-lactamases 
(ESBLs) have rarely been studied for bloodstream infections of Escherichia coli alone. A case-control study 
was undertaken to identify the risk factors associated with bloodstream infections caused by ESBL-
producing E. coli.
METHODS: From January 1, 2005 to June 30, 2007, all patients with a confirmed diagnosis of blood-
stream infection caused by ESBL-producing E. coli were reviewed. Each patient was matched with one con-
trol subject who experienced ESBL-negative E. coli bacteremia during the same study period.
RESULTS: Of the 97 patients diagnosed with ESBL-producing E. coli bacteremia, six were excluded owing 
to incomplete follow-up and missing data. Comparisons were made between 91 patients and their con-
trols. Multivariate analysis identified urinary catheterization [odds ratio (OR) = 6.21, 95% confidence in-
terval (CI) = 1.91–20.25; p = 0.003], prior exposure to antibiotics (OR = 2.93, 95% CI = 1.18–7.30; p = 0.021) 
and previous treatment with oxyimino-cephalosporins (OR = 5.16, 95% CI = 1.03–25.79; p = 0.046) as inde-
pendent predictors for bloodstream infection by ESBL-producing E. coli. Conversely, patients classified as 
having a community-acquired infection were less likely to acquire bacteremia caused by ESBL-producing 
E. coli than those caused by non-ESBL-producing E. coli (OR = 0.22, 95% CI = 0.09–0.57; p = 0.002).
CONCLUSION: More judicious use of antimicrobial agents, especially oxyimino-cephalosporins, and 
avoidance of urinary catheterization may decrease the possibility of ESBL-producing E. coli bacteremia in 
hospitalized patients.
KEYWORDS:  bacteremia, bloodstream infection, case-control study, Escherichia coli, extended-spectrum 
β-lactamase, risk factor
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Introduction
Extended-spectrum β-lactamases (ESBLs) are plasmid-
mediated bacterial enzymes that are able to hydrolyze 
oxyimino-β-lactams (broad-spectrum cephalosporins and 
aztreonam). The marked increase in the incidence of in-
fections due to ESBL-producing Enterobacteriaceae in re-
cent years is of great concern, since the therapeutic options 
for these organisms are limited.1,2 The emergence of CTX-M 
β-lactamases, especially in Escherichia coli, has enabled the 
expansion of this infection in both nosocomial and com-
munity settings.3 Furthermore, patients with infections 
caused by ESBL producers may experience delay in the ini-
tiation of appropriate therapy compared with patients 
with non-ESBL infections.4 The subsequent increased 
risks for clinical failure and death have been shown in sev-
eral studies.5–10 Documenting risk factors and identifying 
vulnerable patient groups are important for the manage-
ment and control of severe infections due to ESBL-
producing organisms. The risk factors for acquisition of 
ESBLs have been studied for Klebsiella pneumoniae, or mul-
tiple infections due to Enterobacteriaceae species,11–14 but 
rarely for E. coli alone. Data focusing on ESBL-producing 
E. coli bloodstream infection are scarce.
In Taiwan, the prevalence of ESBLs has risen in the 
past decade, ranging from 1.5% to 21.9% for various cli-
nical isolates of E. coli.15–17 Although the risk factors for 
infection by ESBL-producing K. pneumoniae and other 
Enterobacteriaceae have been investigated in a few stud-
ies,18,19 no published data dealing with E. coli infection 
alone is available. The objective of this study was to elucidate 
the possible risk factors for ESBL production in patients 
with E. coli bacteremia.
Methods
Data collection
This study was conducted at National Taiwan University 
Hospital, a 2,500-bed major teaching hospital in northern 
Taiwan that provides both primary and tertiary medical 
care. From January 1, 2005 to June 30, 2007, patients older 
than 16 years with at least one positive blood culture of 
ESBL-producing E. coli were reviewed. Only the first 
bacteremic episode in each patient was included in our 
analysis. Patients with bloodstream infections due to 
non-ESBL-producing E. coli during the same period were 
selected as controls. Each case patient was matched in a 
1:1 manner with a control having a positive blood culture 
of non-ESBL-producing E. coli collected on the same day, 
or a day apart. If more than one positive blood culture of 
non-ESBL-producing E. coli was retrieved on the same day as 
the case patient, only the one with the most adjacent chart 
number would be selected as the control. Medical records 
were reviewed retrospectively, and a standardized case 
record form was used to collect the demographic data and 
possible risk factors for ESBL production. These variables 
included (1) the Charlson comorbidity index;20 (2) duration 
of hospital stay; (3) acquisition type (community-acquired, 
healthcare-associated or hospital-acquired); (4) an inten-
sive care unit stay at the time of infection; (5) primary site 
of infection; (6) invasive procedures; and (7) prior antimi-
crobial therapy for at least 48 hours within 30 days prior 
to bacteremia onset.
Bacteriology and antimicrobial susceptibility testing
Strains of E. coli were identified by standard microbiologic 
methods in the microbiology laboratory. Antimicrobial 
susceptibility testing was performed using the Kirby-Bauer 
disk diffusion method. Production of ESBL was confirmed 
using the double-disk synergy test in accordance with the 
Clinical and Laboratory Standards Institute standards.21
Definitions
The date of collection of the first blood culture which 
yielded E. coli was regarded as the date of bacteremia 
onset. Nosocomial infection was defined as an infection 
that occurred > 48 hours after admission to the hospital, 
or an infection that occurred < 48 hours after admission 
in patients that had been transferred from another hospi-
tal. Infection with ESBL-producing E. coli detected within 
the first 48 hours of hospitalization was classified as 
“community-onset” in accordance with the US Centers 
for Disease Control and Prevention definition22 and were 
further classified into community-acquired or healthcare-
associated infections (modified from the study of Siegman-
Igra et al).23 The former definition represents truly 
community-acquired infection, while the latter consists 
of infections in patients recently discharged (≤ 6 months), 
infections associated with invasive procedures performed 
just before, or at the time of, admission and infections in 
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patients admitted from nursing homes. The primary sites 
of infection were identified according to the Centers for 
Disease Control and Prevention definitions.24 Patients 
were classified as immunosuppressed if neutropenia (de-
fined as < 1,000 polymorphonuclear neutrophils cells/mm3), 
hematologic malignancy, corticosteroid therapy (equiva-
lent to > 20 mg prednisolone/day) for at least 2 weeks, 
and/or cancer chemotherapy or radiation therapy were 
documented within 30 days of the onset of bacteremia. 
Patients with serum creatinine level > 3mg/dL, or under 
dialysis, before the onset of bacteremia were considered to 
have chronic renal insufficiency.
Statistical analysis
All statistical analyses were performed using the SAS soft-
ware package (version 9.1; SAS Institute Inc., Cary, NC, 
USA). For univariate analysis, categorical variables were 
compared using χ2 or Fisher’s exact test and continuous 
variables were analyzed with Student’s t test or Mann-
Whitney U test. A p value < 0.05 was considered to be sta-
tistically significant, and all probabilities were two-tailed. 
Multivariate analysis was used to identify independent 
risk factors for ESBL production and was conducted 
using a stepwise logistic regression method.
Results
During the study period, 1,792 adult inpatients were diag-
nosed with E. coli bacteremia. Of these, 97 (5.4%) were 
identified as having bloodstream infections caused by 
ESBL-producing E. coli. Six patients were excluded owing 
to incomplete medical records. The baseline characteris-
tics of the remaining 91 patients and the 91 controls are 
shown in Table 1. By univariate analysis, case patients had 
a higher Charlson comorbidity index (3.9 ± 2.5 vs. 2.6 ± 2.1; 
p < 0.001) and were more likely to be immunosuppressed 
(42.9% vs. 26.4%; p = 0.019). The majority of patients in the 
case group (60.0%) acquired a bloodstream infection in a 
hospital setting, while control patients (55.0%) were more 
often classified as having community-acquired bacte-
remia. The occurrence of the following risk factors was 
also significantly more frequent in the case group: pro-
longed hospital stay, admitted to the intensive care unit 
during the onset of bacteremia, urinary catheterization, 
placement of gastrostomy/nasogastric tube or central 
venous catheters, and mechanical ventilation. Although 
only borderline statistical significance was observed, case 
patients experienced primary bacteremia more frequently 
than control subjects (28.6% vs. 16.5%; p = 0.051), whereas 
urinary tract infection was more likely to be reported in 
the control group (51.6% vs. 37.4%; p = 0.053). A signifi-
cantly higher proportion of case patients had been exposed 
to antimicrobial agents within 30 days prior to the onset 
of bacteremia (63.7% vs. 17.6%; p < 0.001), and oxyimino-
cephalosporins (29.7%) were the most frequently used anti-
microbial agents (Table 2). Multivariate logistic regression 
analysis showed that the independent risk factors associ-
ated with ESBL-production were urinary catheterization 
[odds ratio (OR) = 6.21, 95% confidence interval (CI) = 
1.91–20.25; p = 0.003] and previous antimicrobial therapy 
during 30 days prior to bacteremia onset (OR = 2.93, 95% 
CI = 1.18–7.30; p = 0.021), with oxyimino-cephalosporins 
being associated with the highest risk compared with 
other antimicrobial agents (OR = 5.16, 95% CI = 1.03–25.79; 
p = 0.046). Conversely, community-acquired infection 
(OR = 0.22, 95% CI = 0.09–0.57; p = 0.002) was a negative 
predictor for ESBL production (Table 3).
Discussion
Early identification of ESBL production is becoming in-
creasingly important in terms of appropriate treatment 
and effective infection control in hospitals. Our study 
confirms that patients with urinary catheterization and 
previous use of antimicrobial agents, especially oxyimino-
cephalosporins, are at risk of acquiring bloodstream 
infection due to ESBL-producing E. coli compared with 
non-ESBL-producing E. coli bacteremia, a result similar to 
that in previous reports.25–27 In previous studies, prior expo-
sure to fluoroquinolone was also identified as a potential 
risk factor.26,28 Although this factor was not revealed as 
an independent risk factor for acquiring ESBL-producing 
E. coli bacteremia by multiple analysis in the present study, 
fluoroquinolone was the second most frequently used 
class of antibiotics (25.3%) before bacteremia onset in our 
case group. This may partially explain the low susceptibility 
rate of the ESBL-producing E. coli to fluoroquinolone 
(38.5%) in our hospital (data not shown).
It should be noted that, unlike the situations observed 
in other multidrug resistant bacteria, underlying diseases, 
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e.g. diabetes mellitus, liver cirrhosis and chronic renal in-
sufficiency, were not shown to increase the risk for acquir-
ing bloodstream infections of ESBL-producing E. coli. This 
is consistent with previous studies which demonstrated 
that antibiotic selective pressure, rather than individual 
comorbidities, was the most important factor in the emer-
gence of ESBL-producing isolates.12,26,28–31 Furthermore, 
hospitals and other health-care institutions remain the ma-
jor settings for spreading these multidrug resistant strains 
according to our study. These findings strong support the 
implementation of effective strategies to limit the use 
of extended-spectrum antibiotics and the use of invasive 
procedures, including the insertion of a urinary catheter, 
to control the spread of ESBL-producing E. coli.
Although community-acquired infections (OR = 0.22, 
95% CI = 0.09–0.57; p = 0.002) were a negative predictor of 
ESBL production, it is still a matter of concern that 8.8% 
of case patients were classified as having strictly defined 
community-acquired infections, and the proportion seems 
to be increasing in our hospital (9% in 2006 vs. 12% in 2007). 
In fact, the emergence of ESBL-producing E. coli in the 
community has been increasingly recognized as a global 
problem in recent years.32–34 The majority of cases were at-
tributed to isolates harboring CTX-M type β-lactamases,35 
Table 1. Characteristics and potential risk factors associated with bloodstream infection caused by extended-spectrum β-lactamase-
producing Escherichia colia
Variable Case group Control group Unadjusted OR p
 (n = 91) (n = 91) (95% CI)
Demographic
 Age (yr)b 65.1 ± 17.1 62.6 ± 17.8 – 0.194
 Sex, male 51 (56) 40 (44) 0.62 (0.34–1.10) 0.103
Comorbidities
 Charlson comorbidity scoreb 3.9 ± 2.5 (0–10) 2.6 ± 2.1 (0–8) – < 0.001
 Diabetes mellitus 22 (24.2) 23 (25.3) 0.94 (0.48–1.85) 0.864
 Chronic renal insufficiency 18 (19.8) 10 (11.0) 2.00 (0.87–4.60) 0.100
 Liver cirrhosis 14 (15.4) 18 (19.8) 0.74 (0.34–1.59) 0.436
 Immunosuppression 39 (42.9) 24 (26.4) 2.09 (1.12–3.91) 0.019
Type of infection
 Community-acquired 8 (8.8) 50 (55.0) 0.08 (0.03–0.18) < 0.001
 Healthcare-associated 29 (31.9) 22 (24.2) 1.47 (0.76–2.81) 0.248
 Hospital-acquired 54 (60.0) 19 (20.9) 5.68 (2.94–10.98) < 0.001
Primary site of infection
 Urinary tract 34 (37.4) 47 (51.6) 0.56 (0.31–1.01) 0.053
 Intra-abdominal  22 (24.2) 23 (25.3) 0.94 (0.48–1.85) 0.860
 Primary bacteremia 26 (28.6) 15 (16.5) 2.03 (0.99–4.15) 0.051
 Others 9 (9.9) 6 (6.6) 1.56 (0.53–4.56) 0.420
Risk factors
 Prolonged hospital stay (> 14 days) 34 (37.4) 9 (9.9) 5.43 (2.42–12.20) < 0.001
 ICU stay 13 (14.3) 1 (1.1) 1.92 (1.92–117.27) 0.001
 Gastrostomy/nasogastric tube 29 (31.9) 10 (11.0) 3.79 (1.72–8.36) < 0.001
 Urinary catheterization 32 (35.2) 6 (6.6) 7.68 (3.02–19.53) < 0.001
 Indwelling central venous line 45 (49.5) 14 (15.4) 5.38 (2.67–10.86) < 0.001
 Mechanical ventilation 15 (16.5) 1 (1.1) 17.76 (2.29–137.59) < 0.001
aData presented as n (%) or mean ± standard deviation (range); bMann-Whitney U test. OR = Odds ratio; CI = confidence interval; ICU = intensive 
care unit.
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a fact which has also raised considerable concern in hospi-
tal settings.36 In many countries, including Taiwan, CTX-M 
enzymes have become the most prevalent ESBLs among 
E. coli isolates.3,37,38 In our study population, none of the 
patients classified as having community-acquired infec-
tions were exposed to antimicrobial agents within the 30 
days prior to the onset of bacteremia. In a recent study by 
Kang et al, no predisposing factor was identified in up to 
57% of patients having community-onset bloodstream in-
fections caused by ESBL-producing E. coli.39 The paucity of 
identifiable risk factors for the acquisition of ESBLs poses 
a great challenge for clinical therapeutics and infection 
control in this specific population.
There are limitations in our present study. First, the 
possible coproduction of AmpC enzymes in strains of 
E. coli might result in false negative tests for the detection 
of ESBLs using standard Clinical and Laboratory Standards 
Institute methods.17,37 Second, pulsed-field gel electro-
phoresis was not performed to determine the genetic simi-
larities between all of the identified ESBL-producing E. coli. 
Consequently, we may have underestimated the possibility 
of clonal spread of these resistant isolates within the hos-
pital. Finally, our study was conducted at a single tertiary 
care hospital and our results may not reflect those at other 
institutions with different epidemiologies.
In conclusion, the incidence of ESBL-producing E. coli 
bacteremia may be reduced by curtailing the use of 
oxyimino-cephalosporins and avoiding urinary catheteriza-
tion. Although hospitals remain the major settings in which 
ESBL-producing E. coli bacteremia occur, the emergence 
of ESBL-producing organisms in the community warrants 
further investigation of the epidemiology and risk factors 
within this population.
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